Aquinox Prices Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/25/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Canaccord Genuity Raises Price Target on Aquinox Pharma (AQXP) to $22 on Supporting Evidence for AQX-1125
September 11, 2015 9:24 AM EDTCanaccord Genuity reiterated a Buy rating on Aquinox Pharmaceutical (NASDAQ: AQXP), and raised the price target to $22.00 (from $10.00), on supporting evidence for AQX-1125, and ahead of FDA meetings. Aquinox will meet with FDA, on BPS/IC, for an end of P2 meeting in Nov. to finalize two Ph3's, the 1st of which should start by mid-2016.
Analyst... More
Aquinox Pharma (AQXP) 5.5M Offering Common Stock Prices at $15.50/Share
September 10, 2015 9:15 AM EDTAquinox Pharma (NASDAQ: AQXP) announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $15.50 per share. In addition, Aquinox has granted the underwriters a 30-day option to purchase up to 825,000 additional... More
